ユナイテッド・イミュニティ株式会社
2 known investors
United Immunity develops a myeloid targeting platform using nanoparticles derived from pullulan polysaccharide to deliver therapeutics and vaccines to specific immune cells such as macrophages and dendritic cells. The platform targets applications in cancer immunotherapy and vaccine development by exploiting DC-SIGN receptor selectivity on myeloid cells.